Editor's Choice Notes on three scandals BMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i674 (Published 04 February 2016) Cite this as: BMJ 2016;352:i674 Article Related content Metrics Responses Peer review Related articles Correction Correction Published: 16 February 2016; BMJ 352 doi:10.1136/bmj.i983 Editorial Statutory regulation needed to expose and stop medical fraud Published: 02 February 2016; BMJ 352 doi:10.1136/bmj.i293 Feature Rivaroxaban: can we trust the evidence? Published: 03 February 2016; BMJ 352 doi:10.1136/bmj.i575 Analysis Poor governance in the award of honours and degrees in British medicine: an extreme example of a systemic problem Published: 02 February 2016; BMJ 352 doi:10.1136/bmj.h6952 Feature Dabigatran: how the drug company withheld important analyses Published: 23 July 2014; BMJ 349 doi:10.1136/bmj.g4670 Editorial Pacemaker battery scandal Published: 04 February 2016; BMJ 352 doi:10.1136/bmj.i228 See more Cardiac arrest occurs in three in 10 000 surgeries involving anaesthesia, audit finds BMJ November 20, 2023, 383 p2737; DOI: https://doi.org/10.1136/bmj.p2737 Hypertension: 76 million deaths could be averted by 2050 if treatment coverage improves, says WHO BMJ September 20, 2023, 382 p2154; DOI: https://doi.org/10.1136/bmj.p2154 Capacity problems in the NHS’s cardiac cath labs are harming patients BMJ September 13, 2023, 382 p1953; DOI: https://doi.org/10.1136/bmj.p1953 Threats to human health multiply amid record global temperatures BMJ August 07, 2023, 382 p1819; DOI: https://doi.org/10.1136/bmj.p1819 GP leaders advise practices not to prescribe cholesterol lowering drug inclisiran BMJ August 01, 2023, 382 p1757; DOI: https://doi.org/10.1136/bmj.p1757
